These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28691057)

  • 1. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
    Liu MC; Pitcher BN; Mardis ER; Davies SR; Friedman PN; Snider JE; Vickery TL; Reed JP; DeSchryver K; Singh B; Gradishar WJ; Perez EA; Martino S; Citron ML; Norton L; Winer EP; Hudis CA; Carey LA; Bernard PS; Nielsen TO; Perou CM; Ellis MJ; Barry WT
    NPJ Breast Cancer; 2016; 2():15023-. PubMed ID: 28691057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
    Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
    Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
    Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
    Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
    Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts.
    Kensler KH; Sankar VN; Wang J; Zhang X; Rubadue CA; Baker GM; Parker JS; Hoadley KA; Stancu AL; Pyle ME; Collins LC; Hunter DJ; Eliassen AH; Hankinson SE; Tamimi RM; Heng YJ
    Cancer Epidemiol Biomarkers Prev; 2019 Apr; 28(4):798-806. PubMed ID: 30591591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
    Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
    BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).
    Ligibel JA; Cirrincione CT; Liu M; Citron M; Ingle JN; Gradishar W; Martino S; Sikov W; Michaelson R; Mardis E; Perou CM; Ellis M; Winer E; Hudis CA; Berry D; Barry WT
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26113580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
    Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
    Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.
    Laenkholm AV; Jensen MB; Eriksen JO; Buckingham W; Ferree S; Nielsen TO; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):44-50. PubMed ID: 29202609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research-based PAM50 signature and long-term breast cancer survival.
    Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
    Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
    Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
    Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
    Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
    BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting invasive disease-free survival in ER-positive, HER2-negative early breast cancer using the PAM50 risk-of-recurrence score: a retrospective analysis using single-center long-term follow-up data of postmenopausal Japanese patients.
    Higami A; Takada M; Kawaguchi-Sakita N; Kawashima M; Kawaguchi K; Yamaguchi A; Takeuchi Y; Yamada Y; Toi M
    Int J Clin Oncol; 2024 Nov; 29(11):1715-1720. PubMed ID: 39177880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.
    Jørgensen CLT; Larsson AM; Forsare C; Aaltonen K; Jansson S; Bradshaw R; Bendahl PO; Rydén L
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
    Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
    BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caveolin-1 gene expression provides additional prognostic information combined with PAM50 risk of recurrence (ROR) score in breast cancer.
    Godina C; Belting M; Vallon-Christersson J; Isaksson K; Bosch A; Jernström H
    Sci Rep; 2024 Mar; 14(1):6675. PubMed ID: 38509243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.
    Prat A; Parker JS; Fan C; Perou CM
    Breast Cancer Res Treat; 2012 Aug; 135(1):301-6. PubMed ID: 22752290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
    Dieci MV; Prat A; Tagliafico E; Paré L; Ficarra G; Bisagni G; Piacentini F; Generali DG; Conte P; Guarneri V
    Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.